Back to top
more

Cytokinetics (CYTK)

(Delayed Data from NSDQ)

$53.93 USD

53.93
1,182,895

+1.22 (2.31%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $53.96 +0.03 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CYTK

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cytokinetics, Incorporated [CYTK]

Reports for Purchase

Showing records 241 - 260 ( 308 total )

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 241

09/10/2012

Company Report

Pages: 4

Tirasemtiv Phase IIb Trial Design Finalized, Study to Initiate in 4Q12

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 242

09/10/2012

Daily Note

Pages: 3

Tirasemtiv Phase IIb Trial Design Finalized, Study to Initiate in 4Q12

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 243

09/01/2012

Industry Report

Pages: 5

BIOTECHNOLOGY BALANCE SHEET - August 31st, 2012

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 244

08/10/2012

Industry Report

Pages: 5

BIOTECHNOLOGY BALANCE SHEET

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 245

08/04/2012

Industry Report

Pages: 22

BIOTECH BALANCE SHEET

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 75.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 246

08/01/2012

Daily Note

Pages: 3

FY2Q12 Earnings Update

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 247

08/01/2012

Company Report

Pages: 5

FY2Q12 Earnings Update

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 248

07/30/2012

Daily Note

Pages: 3

FY2Q12 Earnings Preview

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 249

07/30/2012

Company Report

Pages: 4

FY2Q12 Earnings Preview

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 250

07/28/2012

Industry Report

Pages: 21

BIOTECH BALANCE SHEET

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 75.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 251

07/26/2012

Daily Note

Pages: 3

Omecamtiv mecarbil: a promising new drug in systolic heart failure

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 252

07/26/2012

Company Report

Pages: 3

Omecamtiv mecarbil: a promising new drug in systolic heart failure

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 253

07/02/2012

Company Report

Pages: 5

Raises $60MM to Fully Fund Phase IIb Study - Updating our Models

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 254

07/02/2012

Daily Note

Pages: 3

Raises $60MM to Fully Fund Phase IIb Study - Updating our Models

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 255

05/24/2012

Daily Note

Pages: 3

Another Step Forward: Omecamtiv Progresses to Second Cohort of ATOMIC

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 256

05/24/2012

Company Report

Pages: 4

Another Step Forward: Omecamtiv Progresses to Second Cohort of ATOMIC

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 257

05/11/2012

Industry Report

Pages: 8

Crowdsourcing AAN: Recap of R&R and Pharm3r Twitter Survey

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 258

05/11/2012

Industry Report

Pages: 8

Life Sciences: Crowdsourcing AAN: Recap of R&R and Pharm3r Twitter Survey

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 259

05/11/2012

Industry Report

Pages: 3

Life Sciences: Crowdsourcing AAN: Recap of R&R and Pharm3r Twitter Survey

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 260

04/27/2012

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party